Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $7.73 USD
Change Today -0.14 / -1.78%
Volume 86.4K
As of 8:10 PM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

chemocentryx inc (CCXI) Key Developments

ChemoCentryx, Inc. Reports Consolidated Financial Results for the Fourth Quarter and Year Ended December 31, 2014

ChemoCentryx, Inc. reported consolidated financial results for the fourth quarter and year ended December 31, 2014. For the quarter the company reported, no revenue compared to $0.7 million in the same period in 2013. The decrease in revenues from 2013 to 2014 was primarily due to funding of clinical support from former partner, GlaxoSmithKline (GSK), for CCX168, the Company's C5aR inhibitor, in 2013. Net loss was $12.2 million for the fourth quarter of 2014 compared to $9.5 million in the same period in 2013. Loss from operations was $12.290 million compared to $9.671 million a year ago. Basic and diluted net loss per share was $0.28 compared to $0.22 a year ago. For the year the company reported, no revenue compared to $6.1 million in the same period in 2013. Loss from operations was $47.399 million compared to $39.115 million a year ago. Net loss was $46.929 million compared to $38.673 million a year ago. Basic and diluted net loss per share was $1.08 compared to $0.95 a year ago.

ChemoCentryx, Inc. to Report Q4, 2014 Results on Mar 12, 2015

ChemoCentryx, Inc. announced that they will report Q4, 2014 results at 5:00 PM, US Eastern Standard Time on Mar 12, 2015

ChemoCentryx, Inc., Q4 2014 Earnings Call, Mar 12, 2015

ChemoCentryx, Inc., Q4 2014 Earnings Call, Mar 12, 2015

ChemoCentryx, Inc. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-03-2015 08:00 AM

ChemoCentryx, Inc. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-03-2015 08:00 AM. Venue: The Boston Marriott Copley Place, Boston, Massachusetts, United States. Speakers: Thomas J. Schall, Founder, Chairman, Chief Executive Officer and President.

ChemoCentryx, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-14-2015 04:00 PM

ChemoCentryx, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-14-2015 04:00 PM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Thomas J. Schall, Founder, Chairman, Chief Executive Officer and President.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CCXI:US $7.73 USD -0.14

CCXI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CCXI.
View Industry Companies
 

Industry Analysis

CCXI

Industry Average

Valuation CCXI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CHEMOCENTRYX INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.